Cereno Scientific, a clinical stage biotech with an innovative portfolio in common and rare CVD, appoints Julia Fransson as Director of Business Development
Cereno Scientific (Nasdaq First North: CRNO B) today announced that Julia Fransson has joined the company as Director of Business Development. She joins the clinical stage biotech at an exciting point of the company’s growth journey, in developing innovative treatments for common and rare cardiovascular disease, with lead candidate drug CS1 in phase II in orphan disease PAH which is to deliver top line study results by Q2 this year.“As our innovative portfolio of candidate drugs are progressing well, we need to scale our capacity on the business development side of our operations. Julia